19:02 , May 31, 2018 |  BC Innovations  |  Product R&D

Lilly’s new leaf

As Daniel Skovronsky takes the helm of Eli Lilly and Co.’s R&D business, his goal is to shake the pharma’s reputation as a fast-follower and instead advance first-in-class therapeutics with large effect sizes. To get...
16:28 , Oct 6, 2017 |  BC Week In Review  |  Company News

Eli Lilly management changes

On Sept. 29, Eli Lilly and Co. (NYSE:LLY) announced several managerial changes, including the promotion of SVP of Clinical and Product Development Dan Skovronsky to SVP for science and technology and president of Lilly Research...
22:57 , Sep 29, 2017 |  BC Extra  |  Company News

Eli Lilly management changes

Eli Lilly and Co. (NYSE:LLY) announced several managerial changes on Friday, including the promotion of SVP of Clinical and Product Development Dan Skovronsky to SVP for science and technology and president of Lilly Research Labs...
07:00 , Mar 24, 2016 |  BC Innovations  |  Translation in Brief

The tau of imaging

Two studies have for the first time combined live imaging of tau and β-amyloid in Alzheimer's disease (AD) patients and shown that while tau levels correlate more strongly with memory loss and cognitive decline, the...
07:00 , Jun 1, 2015 |  BioCentury  |  Finance

(O)sage investing

With its academic partnering model fleshed out and half a dozen life sciences exits under its belt, Osage University Partners was able to raise a second fund twice the size of its first. Osage's William...
07:00 , Oct 21, 2013 |  BioCentury  |  Regulation

Limiting amyloid access

A decision by the Centers for Medicare & Medicaid Services to require coverage with evidence development for beta amyloid imaging agents means that Medicare patients will probably have to wait at least a few more...
07:00 , Apr 22, 2013 |  BC Week In Review  |  Company News

Eli Lilly, Siemens deal

Eli Lilly acquired two PET tracers from Siemens to image microtubule-associated protein tau (MAPT; tau; FTDP-17 ) tangles in the brain of Alzheimer's disease patients. Lilly will initially focus on incorporating the technologies into its...
08:00 , Jan 21, 2013 |  BC Week In Review  |  Clinical News

Amyvid florbetapir regulatory update

The European Commission approved Amyvid florbetapir from Eli Lilly as a PET imaging agent to estimate beta amyloid neuritic plaque density in patients with cognitive impairment who are being evaluated for Alzheimer's disease and other...
02:28 , Jan 16, 2013 |  BC Extra  |  Company News

EC approves Lilly's imaging agent Amyvid

The European Commission approved Amyvid florbetapir from Eli Lilly and Co. (NYSE:LLY) as a PET imaging agent to estimate beta amyloid neuritic plaque density in patients with cognitive impairment who are being evaluated for Alzheimer's...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Clinical News

Amyvid florbetapir regulatory update

CMS's Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) will meet on Jan. 30, 2013, to discuss a National Coverage Assessment (NCA) for PET imaging of brain beta amyloid for diagnosing and managing dementia and...